These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27526367)

  • 1. Effect of glucagon-like peptide-1 on major cardiovascular outcomes in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Ding S; Du YP; Lin N; Su YY; Yang F; Kong LC; Ge H; Pu J; He B
    Int J Cardiol; 2016 Nov; 222():957-962. PubMed ID: 27526367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.
    Qin J; Song L
    BMC Endocr Disord; 2022 May; 22(1):125. PubMed ID: 35546664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta-Analysis of Randomized-Controlled Trials.
    Hosseinpour A; Sood A; Kamalpour J; Zandi E; Pakmehr S; Hosseinpour H; Sood A; Agrawal A; Gupta R
    Clin Cardiol; 2024 Jul; 47(7):e24314. PubMed ID: 38953365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials.
    Al Yami MS; Alfayez OM; Alsheikh R
    Heart Lung Circ; 2018 Nov; 27(11):1301-1309. PubMed ID: 29887418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis.
    Gargiulo P; Savarese G; D'Amore C; De Martino F; Lund LH; Marsico F; Dellegrottaglie S; Marciano C; Trimarco B; Perrone-Filardi P
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1081-1088. PubMed ID: 29113708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
    Diabetes Obes Metab; 2014 Jan; 16(1):38-47. PubMed ID: 23829656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis.
    Howse PM; Chibrikova LN; Twells LK; Barrett BJ; Gamble JM
    Am J Kidney Dis; 2016 Nov; 68(5):733-742. PubMed ID: 27528374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials.
    Mabilleau G; Mieczkowska A; Chappard D
    J Diabetes; 2014 May; 6(3):260-6. PubMed ID: 24164867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of intensive glucose lowering in treatment of type 2 diabetes mellitus on cardiovascular outcomes: A meta-analysis of data from 58,160 patients in 13 randomized controlled trials.
    Fang HJ; Zhou YH; Tian YJ; Du HY; Sun YX; Zhong LY
    Int J Cardiol; 2016 Sep; 218():50-58. PubMed ID: 27236108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials.
    Jia X; Alam M; Ye Y; Bajaj M; Birnbaum Y
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):65-72. PubMed ID: 29445896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
    He L; Wang J; Ping F; Yang N; Huang J; Li Y; Xu L; Li W; Zhang H
    JAMA Intern Med; 2022 May; 182(5):513-519. PubMed ID: 35344001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of glucagon-like peptide-1 agents on left ventricular function: systematic review and meta-analysis.
    Liu R; Li L; Chen Y; Yang M; Liu H; Yang G
    Ann Med; 2014 Dec; 46(8):664-71. PubMed ID: 25134954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential cardiovascular effects of incretin-based therapies.
    Deacon CF; Marx N
    Expert Rev Cardiovasc Ther; 2012 Mar; 10(3):337-51. PubMed ID: 22390806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Safety and Efficacy of GLP-1 Receptor Agonists in Heart Failure Patients: A Systematic Review and Meta-Analysis.
    Merza N; Akram M; Mengal A; Rashid AM; Mahboob A; Faryad M; Fatima Z; Ahmed M; Ansari SA
    Curr Probl Cardiol; 2023 May; 48(5):101602. PubMed ID: 36682393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies.
    Chilton R; Wyatt J; Nandish S; Oliveros R; Lujan M
    Am J Med; 2011 Jan; 124(1 Suppl):S35-53. PubMed ID: 21194579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials.
    Wu S; Sun F; Zhang Y; Yang Z; Hong T; Chen Y; Zhan S
    J Clin Pharm Ther; 2014 Feb; 39(1):7-13. PubMed ID: 24127768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interventions in type 2 diabetes mellitus and cardiovascular mortality-An overview of clinical trials.
    Burggraaf B; Castro Cabezas M
    Eur J Intern Med; 2017 Jul; 42():1-15. PubMed ID: 28554780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethnic/Racial and Geographic Disparities on Major Cardiovascular Events in Glucagon Like Peptide-1 receptor Agonists Trials: A Meta-Analysis.
    Lavalle Cobo A; Masson W; Lobo M; Barbagelata L; Forte E; Corral P; Nogueira JP
    Curr Probl Cardiol; 2023 Nov; 48(11):101940. PubMed ID: 37422042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular safety of incretin-based therapy for type 2 diabetes: A meta-analysis of randomized trials.
    Mahmoud AN; Saad M; Mansoor H; Elgendy AY; Barakat AF; Abuzaid A; Mentias A; Elgendy IY
    Int J Cardiol; 2017 Mar; 230():324-326. PubMed ID: 28043676
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.